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Abstract
Introduction. Gaucher cells (GCs), the lipid-laden storage macrophages, are the pathologic hallmark of Gaucher 
disease (GD). They are typically 20–100 µm in diameter with eccentrically placed nuclei and cytoplasm with cha-
racteristic crinkles and striations. A few previous observations have indicated that sometimes GD patients may 
display morphology of GCs which is different from this classical description. The aim of our study was to explore 
the morphological polymorphism of GCs in patients with untreated GD type 1 (GD1). 
Material and methods. May-Grünwald Giemsa stained bone marrow smears (BM-S) from 6 patients with sporadic 
GD1 were analysed; each patient sample consisted of two slides where all GCs and non-Gaucher cell macrophages 
were counted. We have defined for the study purposes and examined the following features of GCs which were 
considered as atypical: (1) foamy cytoplasm, (2) centrally placed nucleus, (3) cell diameter > 100 µm, (4) multinuc-
learity, (5) syncytial morphology, (6) unusually large cytoplasmic projections, and (7) apparent haemophagocytosis.
Results. All analysed patients showed 22–40% GCs with atypical cytomorphology (median 29%). The median 
number of atypical features of GCs was 10 per patient (range 6–13). Multinuclearity was the most common 
atypical feature of GCs, followed by erythrophagocytosis and foamy cytoplasm. There was a strong positive 
correlation between erythrophagocytosis and foamy cytoplasm in GCs (Spearman’s rank correlation coefficient: 
0.9). Although majority of atypical GCs had one atypical feature, there was a considerable amount of GCs pre-
senting ≥ 2 atypical features.
Conclusions. Untreated patients with GD1 often show a considerable proportion of GCs with atypical cyto-
morphology. The knowledge of possible atypical variant forms of GCs can contribute to a quicker and accurate 
diagnosis of GD, and minimize the risk for misdiagnosis. To the best of our knowledge, this is the first published 
report on atypical cytomorphology of GCs in untreated patients with GD1. (Folia Histochemica et Cytobiologica 
2015, Vol. 53, No. 1, 62–69)
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Introduction
Gaucher disease (GD), although rare, is one of the 
most common glycolipid storage disorders, caused 
by an inherited deficiency of the lysosomal enzyme, 
glucocerebrosidase, arising from autosomal recessive 
mutations in the GBA1 gene (1q21) [1, 2]. 
Cytomorphologically noticeable lysosomal ac-
cumulation of the uncleaved glucocerebroside is 
restricted, for not completely understood reasons, to 
one cell type belonging to the monocyte-macrophage 
series [3, 4]. These lipid-laden storage macrophages, 
referred to as ‘Gaucher cells’, are the pathologic 
hallmark of GD [5–7]. Gaucher cell (GC) is typi-
cally a large cell of 20–100 µm diameter with small, 
eccentrically placed nucleus, has slightly basophilic 
cytoplasm with characteristic crinkles or striations 
described as having a ‘crumpled or wrinkled tissue 
paper’ appearance (Figure 1A) [2, 5, 6]. Infiltrates of 
GCs can be found in organs and tissues enriched in 
cells of the mononuclear phagocyte system, such as 
spleen, liver and in particular, bone marrow [5–11].
Three clinical types of GD are distinguished ac-
cording to the absence (type 1) or presence (types 2 
and 3) of neurological symptoms and the dynamics 
of developing clinical signs [1, 2, 12]. The most 
prevalent form of GD is non-neuronopathic GD 
type 1 (GD1). GD1 is a slowly progressive illness, 
and clinical picture can vary from severe, lethal cases 
diagnosed in early childhood to completely asymp-
tomatic patients [13–16]. Currently, GD is treatable 
and in the European Union there are two treat- 
ment options available for patients: (1) enzyme 
replacement therapy (ERT) with macrophage-tar-
geted recombinant glucocerebrosidase (Cerezyme®, 
Genzyme Corporation, Cambridge, MA, USA; 
VPRIV®, Shire HGT, Lexington, MA, USA), and 
(2) substrate reduction therapy (SRT) with miglu-
stat/N-butyldeoxynojirimycin (Zavesca®, Actelion 
Pharmaceuticals, Allschwil, Switzerland) [17–20].
Only a few previous observations have indicated 
that sometimes GCs may display cytomorphology 
which is different from the classical description of 
GC. These atypical GCs may be of a larger size or may 
contain a vacuolated, foamy cytoplasm, a centrally 
placed nucleus, more than one nucleus, cytoplasmic 
projections, hemosiderin and/or apparent phagocy-
tosis of haematopoietic cells and/or thrombocytes 
[21–28]. However, so far, there were no published 
studies examining this issue.
The aim of our study was to explore the morpho-
logical polymorphism of GCs present in the bone 
marrow of patients with GD1.
Material and methods
Patients and material collection. Between 2002 and 2014, 
16 of 35 (46%) Swedish patients with GD1 were followed at 
the Karolinska University Hospital in Stockholm. Of these, 
6 patients with sporadic GD1 who initially underwent diagno-
stic bone marrow examination were included in this analysis.
In all patients studied, the diagnosis of GD was con-
firmed by low glucocerebrosidase activity in peripheral 
blood leukocytes (Table 1). All patients also demonstrated 
increased plasma chitotriosidase activity. Both enzymes 
were assessed by a reference laboratory according to 
standard practice [6, 19]. Further, direct DNA sequencing 
performed at the Academic Medical Centre in Amsterdam, 
Netherlands, revealed mutations in the GBA1 gene in all 
cases. The patients’ files were reviewed to collect relevant 
clinical data. All patients provided their informed consent. 
The basic patient characteristics are summarized in Table 1.
Bone marrow samples were collected under local 
anaesthesia from an entry site on the posterior iliac crest 
of patients in the prone position. May-Grünwald Giemsa 
(MGG) staining of bone marrow smears (BM-S) had pre-
viously been performed by laboratory staff according to the 
Table 1. Patient characteristics
Feature (n = 6) Result
Age (years)
   range 
   mean
   median
21–84
62
65
Sex
   male
   female 
4 (67%)
2 (33%)
Splenectomy 3 (50%)
Bone disease
   symptomatic
   radiological
3 (50%) 
6 (100%)
Glucocerebrosidase activity in peripheral blood 
leukocytes (ref.: 2.1–3.8 µkat/kg protein)
   range
   mean
   median
0.10–0.59
0.39
0.42
Chitotriosidase activity in plasma  
(ref.: > 40 nkat/L)
   range
   mean
   median
1322–9743
3339
2309
GBA1 gene mutations
   c.1226A>G/c.1226A>G
   c.1226A>G/other1
   other/other2
1 (17%)
4 (67%)
1 (17%)
1c.721G>A (1 patient); c.1448T>C (2 patients); c.1448T>C,  
c.1483G>C, c.1497G>C (1 patient) 
2c.798C>G/c.1040T>G
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standard procedures of the Centrum for Cell Analysis at 
the Pathology Department, Karolinska University Hospital 
Huddinge, and then re-assessed for the study purposes. 
The study protocol was developed according to the ethical 
standards of the Declaration of Helsinki and approved by 
the local ethics committee.
Characteristics of atypical Gaucher cells and non-Gaucher 
cell macrophages. MGG-stained BM-S were analysed at the 
40 × objective of Olympus BX 40 microscope (Olympus, 
Tokyo, Japan). Each patient sample consisted of two slides 
in which all GCs and non-GC macrophages were counted 
(i.e., total cell count).
We have defined for the study purposes and examined 
the following features of GCs which were considered as 
atypical: (1) foamy cytoplasm (involving > 10% of the 
cytoplasm), (2) a centrally placed nucleus (the shortest 
distance between the nuclear membrane and the cytoplasmic 
membrane > 2/3 of the cell radius), (3) GC diameter > 100 µm, 
(4) multi-nuclear GCs, (5) unusually large cytoplasmic 
projections (processes) that are longer then the longest 
diameter of the cell nucleus and thinner than the cells shor-
test diameter [21, 22], and (6) apparent haemophagocytosis 
(Figure 1, B–H). Multi-nuclear GCs larger than 100 µm 
were classified as a (7) syncytium. The phagocytosed cells 
were categorized as erythrocytes, erythroblasts, lymphocytes, 
Figure 1. Gaucher cells showing typical (A) and atypical (B–H) morphology. A. Typical Gaucher cell (GC) with fibrillary 
cytoplasm and an eccentric placed nucleus; B. GC with foamy cytoplasm and almost central nucleus; C. A syncytium of 
GCs with phagocytosed neutrophilic granulocytes; D. GC with cytoplasmic projections and two nuclei; E. GC with two 
nuclei and thrombophagocytosis; F. Foamy GC with hemosiderin grains; G. GC with erythrophagocytosis; H. GC with 
phagocytosis of erythroblasts, neutrophilic granulocytes, an eosinophilic granulocyte and some unidentified nucleated 
cells. Bone marrow smears, May-Grünwald Giemsa staining
A B
C
D
E
F
HG
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granulocytes, myelopoietic precursors, thrombocytes and 
unidentified nuclear cells.
The diameter and radius of the cells were estimated by 
comparison with an erythrocyte (approx. 7 µm), a reticulo-
cyte (7–10 µm) or a band/segmented granulocyte (approx. 
14 µm).
The non-GC macrophages were identified based on the 
absence of the fibrillary structure of the cytoplasm without 
being foamy, though they could contain a few vacuoles. The 
non-GC macrophages could sometimes also be smaller than 
20 µm in diameter but always bigger than 18 µm in diameter.
Digital imaging of BM-S was carried out using a Nikon 
DX m 1200F digital camera mounted on the Nikon Eclip-
se E1000 microscope (Nikon, Tokyo, Japan) with a 40 × 
objective.
Statistical analysis. The non-parametric Spearman’s rank 
correlation coefficient was used to assess how well the 
relationship between two variables can be described using 
a monotonic function.
Results
A total of 12 BM-S from 6 patients with untreated 
GD1 were evaluated. The numbers and proportions 
of typical and atypical GCs as well as non-GC ma-
crophages found in the BM-S are showed in Table 2.
The median total number of all GCs (typical and 
atypical) identified on two BM-S from one patient was 
533 (range 132–2159) and the median percentage of 
GCs with atypical features among all GCs was 29% 
(range 22–40%).
The median total number and percentage of non-
GC macrophages identified on two BM-S from one 
patient was very low as compared to GCs: 3 (range 
2–17) and 1% (range 1–2%), respectively.
The repertoire of atypical features of GCs in the 
BM-S ranged from 6 to 13 per patient (median value: 
10). The youngest patient (patient #4, splenectomi-
sed) had the lowest proportion of atypical GCs and 
the smallest repertoire of atypical features followed 
by the patient #3 (unsplenectomised). GCs with 
multinuclearity and GCs presenting with erythropha-
gocytosis, phagocytosis of erythroblasts, thrombocytes 
and unidentified nuclear cells, could be found in all 
patients (Table 3).
Foamy cytoplasm has been found in all but one 
patient (median value: 6% of atypical GCs; range 
0–15%). There were no foamy GCs in the BM-S 
from the patient #4 who was the youngest one in the 
studied group. Furthermore, the two oldest patients 
had the highest proportion of foamy GCs (Spearman’s 
rank correlation coefficient: 0.8).
GCs with a centrally placed nucleus could be found 
in 5 (83%) patients (median value: 1% of atypical 
GCs; range 0–2%); all of them had also foamy GCs. 
The GCs with central nucleus had more often a foamy 
cytoplasm (16%) than the GCs with an eccentrically 
located nucleus (11%).
Syncytial morphology of GCs was only found in 
two patients. Multinuclearity was found in all patients, 
the proportions ranged from 5–18% of atypical GCs 
(median of 12%). Multinuclear GCs with a diameter 
of > 100 µm that is GCs with syncytial morphology 
were found only in the BM-S from patients #5 and 
#6, and they were very few (up to 1% of all GCs).
Cytoplasmic projections could be found in 5 patients 
(median value: 0.5% of atypical GCs; range 0–2%). 
Erythrophagocytosis could be found in all patients 
ranging from 5–15% of atypical GCs (median value: 
6%). Phagocytosis of erythroblasts could also be 
found in all patients (median value: 1% of atypical 
GCs; range 0–2%). Although lymphophagocytosis 
could be found in 5 patients, granulophagocytosis in 
4 patients, and phagocytosis of myeloid precursors in 
one patient, the proportions of those GCs were close 
to 0%. Thrombophagocytosis could be found in all 
patients ranging from 1–9% of atypical GCs (median 
Table 2. Number and percentage of counted Gaucher cells and non-Gaucher cell macrophages
Pt S/A (years) Gaucher cells Non-Gaucher cells A total number of GCs  
and non-GCs
Typical morphology Atypical morphology All GCs
1 M/81 155 (60%) 102 (40%) 257 (99%) 3 (1%) 260 
2 M/84 620 (64%) 346 (36%) 966 (98%) 15 (2%) 981 
3 F/56 508 (77%) 155 (23%) 663 (99%) 4 (1%) 667 
4 F/21 103 (78%) 29 (22%) 132 (99%) 2 (1%) 134 
5 M/65 278 (69%) 126 (31%) 404 (98%) 7 (2%) 411 
6 M/66 1585 (73%) 574 (27%) 2159 (99%) 17 (1%) 2176
Each patient sample consisted of two bone marrow slides in which all Gaucher cells and non-Gaucher cell macrophages were counted. Abbrevia-
tions: Pt — patient; S — sex; A — age; M — male; F — female; GCs — Gaucher cells; non-GCs — non-Gaucher cell macrophages
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2.5%), and phagocytosis of unidentified nuclear cells 
could be found in all patients (0–3% of atypical GCs, 
median value 1.5%).
Although most atypical GCs only had one atypical 
feature, there was a considerable amount of the GCs 
presenting two or even more atypical features (Table 4). 
In total, there were 35 different combinations of 
2 atypical features and 55 combinations of ≥ 3 atypical 
features. The most common combination of 2 atypical 
features was multinuclearity and erythrophagocytosis 
followed by foamy cytoplasm and erythrophagocyto-
sis. The most common combination of ≥ 3 atypical 
features was foamy cytoplasm, multinuclearity and 
erythrophagocytosis followed by multinuclearity, 
erythrophagocytosis and thrombophagocytosis.
Discussion
Gaucher disease is well known for its striking phenoty-
pic diversity, which can complicate a timely diagnosis. 
Since GD is rare and its symptoms can be caused by 
many other conditions, it is not likely to be suspected 
in a patient not belonging to the more affected popu-
lations such as Ashkenazi Jews or the population of 
Norrbotten (the northernmost Swedish region) [5–6, 
10, 12, 19–31].
Historically, diagnosis of GD was usually based on 
morphological examination of the affected organ (e.g., 
bone marrow, spleen, liver) [6, 8, 29]. Until 1966, when 
pseudo-Gaucher cells were described for the first time 
in chronic myeloid leukaemia, it was believed that the 
Table 4. Number and percentage of counted Gaucher cells showing one, two, three or more atypical features
Pt S/A (years) Gaucher cells presenting with
One atypical feature Combination of 2 atypical features Combination of ≥ 3 atypical features
1 M/81 85 (33%) 17 (7%) 0
2 M/84 290 (30%) 47 (5%) 9 (1%)
3 F/56 139 (21%) 12 (2%) 4 (1%)
4 F/21 26 (20%) 3 (2%) 0
5 M/65 100 (25%) 22 (5%) 4 (1%)
6 M/66 463 (21%) 78 (4%) 33 (2%)
Abbreviations: Pt — patient; S — sex; A — age; M — male; F — female
Table 3. Number and percentage of Gaucher cells showing particular features of atypical cytomorphology
Pt S/A 
(years)
Total 
number of 
atypical 
GCs
Number of Gaucher cells showing particular features of atypical morphology 
(% of all the patient’s GCs)
Foamy 
CP
Central 
nucleus
D > 
100 mm
Multi-
nuclear
Syncyt CP  
project
Apparent haemophagocytosis of particular cell type
Ery EryBl Lym Gra Mye Plt Uns
1 M/81 102 18  
(7%)
5  
(2%)
0 30  
(12%)
0 1  
(0.4%)
34  
(13%)
5  
(2%)
1  
(0.4%)
2  
(1%)
0 18  
(7%)
5  
(2%)
2 M/84 346 146 
(15%)
10  
(1%)
0 84  
(9%)
0 3  
(0.3%)
146 
(15%)
4 
(0.4%)
1  
(0.1%)
5  
(1%)
0 7  
(1%)
7  
(1%)
3 F/56 155 42  
(6%)
14  
(2%)
0 33  
(5%)
0 0 53  
(8%)
9  
(1%)
1  
(0.2%)
0 0 16  
(2%)
8  
(1%)
4 F/21 29 0 0 0 17  
(13%)
0 2  
(2%)
7  
(5%)
1  
(1%)
0 0 0 1  
(1%)
4  
(3%)
5 M/65 126 23  
(6%)
4  
(1%)
2  
(0.5%)
57  
(14%)
2  
(0.5%)
3  
(1%)
21  
(5%)
5  
(1%)
2  
(0.5%)
2  
(0.5%)
0 36  
(9%)
1  
(0.2%)
6 M/66 574 45  
(2%)
16  
(1%)
2  
(0.1%)
393 
(18%)
2  
(0.1%)
28  
(1%)
104  
(5%)
12  
(1%)
1  
(0.1%)
9  
(0.4%)
2  
(0.1%)
68  
(3%)
46  
(2%)
Abbreviations: Pt — patient; S — sex; A— age; M — male; F — female; GCs — Gaucher cells; CP — cytoplasm; D — diameter; Syncyt — syn-
cytial morphology; CP project — cytoplasmic projections; Ery — erythrocytes; EryBl — erythroblasts; Lym — lymphocytes; Gra — granulocytes; 
Mye — myeloid precursors; Plt — blood platelets; Uns — unspecified nuclear cell. Percentage may exceed 100 due to rounding and/or presenting 
of ≥ 2 features by some atypical GCs
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presence of GCs in bone marrow was pathognomonic 
of GD [32]. It must be stressed that currently the gol-
den standard for definitive diagnostics of GD requires 
confirmation of reduced enzymatic activity of gluco-
cerebrosidase in leukocytes, cultured fibroblasts, or 
amniocytes obtained during prenatal diagnosis [1, 2]. 
Enzymatic assays should therefore always be applied 
in suspected cases. Measurement of glucocerebrosi-
dase is supplemented by GBA1 mutation analysis [33].
In a general population, in patients without any pre-
viously known GD-affected family member, frequent 
symptoms of GD, such as thrombocytopenia or sple-
nomegaly, often lead to haematological work-up with 
aspiration biopsy of bone marrow for the cytological 
assessment of BM-S [2, 6, 7, 10]. This can disclose the 
presence of GCs and lead to the final diagnosis [2, 6].
The results of our recently published study showed 
that aspiration biopsy of bone marrow may provide 
only a very few GCs for assessment (median: 4 GCs; 
range 1–18) [31]. Therefore knowledge about unusual, 
atypical morphology of GCs could be crucial in giving 
a first clue towards GD diagnosis in some patients.
In the present study, all analysed patients had 
multinucleated GCs and multinuclearity was the most 
common atypical feature of GCs. However, there was 
variability in the proportions of multinuclear GCs 
between the patients. There are only few previous 
studies in which multinuclear GCs have been noted 
[5, 21, 26], and these observations have never lead to 
any systematic research on this issue.
Multinucleated giant cells have been observed 
intermixed with typical GCs in an ultrastructural study 
by Takahashi and Naito [34]. Syncytial multinuclear 
giant cells with striated cytoplasm from a GD1 patient 
have only been described by Ziyeh and Harzer, who 
suggested that these cells might be osteoclasts which 
are specialized multinucleated macrophages [25].
Although majority of stored glucocerebroside in 
GCs is of erythrocyte origin, apparent erythropha-
gocytosis by GCs in bone marrow has been infrequ-
ently reported [5, 22, 26, 28, 35]. The erythrocytes of 
untreated GD patients have been found by Bratosin 
et al. to have an altered morphology and reduced 
viability which may promote erythrophagocytosis [36]. 
According to them, the alterations in erythrocyte 
morphology and viability disappeared after 9 months 
of ERT. We found erythrophagocytosis in BM-S 
from all patients and it was the second most common 
atypical feature of GCs. Of note, there was a strong 
positive correlation between erythrophagocytosis and 
the presence of foamy cytoplasm in GCs (Spearman’s 
rank correlation coefficient: 0.9).
Atypical macrophages of soap bubble or foamy 
appearance are usual findings in the bone marrow 
of patients with Niemann-Pick disease [37, 38]. Wil-
liam Bloom in 1925 provided probably the earliest 
description and microscopic pictures of foamy trans-
formed macrophages in Niemann-Pick disease [39]. 
However, some other diseases and conditions 
including Wolman disease, Tangier disease, hyper-
cho-lesterolaemia, hyperchylomicronaemia, adult 
cholesteryl ester storage disease (CESD), hyperuri-
caemia, or long-term total parenteral nutrition may 
also lead to the formation of atypical foamy macro-
phages [25, 40–42].
Foamy transformed GCs were first reported by 
Elleder in 1992, in the autopsy report concerning two 
patients, one with GD type 2 and one with GD type 1 [24]. 
The author proposed that foamy transformation of 
GCs could depend on an accentuation of lipid storage, 
but also on an abnormal storage pattern triggered by 
external factors (e.g. infection, ischaemia). In 2009, 
Hůlková et al. published an autopsy case of a 59 year 
old woman diagnosed with GD1 which was treated 
with ERT [11]. The authors found foamy or vacuolated 
GCs in the bone marrow which were located closely 
to the adipose tissue. Ultrastructural examinations of 
these foamy GCs revealed lipid droplets in the cytosol, 
separated from the lysosomal compartments [11]. 
Two years later, in 2011 our group reported for the 
first time foamy GCs in the living individual [28]. This 
latter finding has led us to conduct the present study 
to investigate polymorphism of GCs in untreated 
patients with GD1.
Foamy cytoplasm was the third most common 
atypical feature in the GCs in our study. It is not 
excluded that there might be a positive correlation 
between age and proportion of foamy GCs; however, 
a larger number of patients should be assessed before 
drawing any final conclusions.
Only a very small proportion of GCs in each of 
our GD1 patients had a centrally located nucleus and 
there was no significant variation between the patients 
considering GCs with central nucleus.
Gaucher cells with cytoplasmic projections have 
previously been described in two electron-microscopic 
studies. Pennelli et al. reported a ‘small pseudopodia’ 
or ‘ridge-like projections similar to microvilli’ [22]. 
In a study by DeMarsh and Kautz long finger-like 
projections were occasionally encountered [21]. In 
the present study, GCs with cytoplasmic projections 
were present in all but one GD1 patient. However, 
the proportions of GCs with cytoplasmic projections 
were always very small.
We conclude that untreated patients with GD1 
often show a reasonable proportion of GCs with 
atypical cytomorphology. Initial symptoms of spo-
radic GD1 often lead to haematological diagnostics, 
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including bone marrow examination. Therefore, 
knowledge of possible atypical variant forms of GCs 
in BM-S can contribute to a quicker and accurate 
diagnosis of GD, and minimize the risk for misdia-
gnosis. To the best of our knowledge, this is the first 
published report on atypical cytomorphology of GCs 
in untreated patients with GD1.
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